热门资讯> 正文

展望治疗宣布任命首席执行官

2025-07-01 20:22

Outlook Therapeutics (NASDAQ:OTLK) has named Bob Jahr as chief executive officer and a member of its board.
Jahr succeeds interim CEO Lawrence A. Kenyon, who will continue as chief financial officer and board member.
Jahr brings over 20 years of commercial leadership in biopharma, including roles at Sobi NA, UCB Pharma, and Amgen.
Source: Press release

More on Outlook Therapeutics

Outlook Therapeutics drops 17%, prices $13M stock offering
Outlook Therapeutics gets FDA review acceptance for wet AMD treatment
Seeking Alpha’s Quant Rating on Outlook Therapeutics
Historical earnings data for Outlook Therapeutics
Financial information for Outlook Therapeutics

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。